Study of HS-10241 in people with liver problems and healthy liver function
Part of Cancer clinical trials.
This trial tests how the drug HS-10241 works in people with mild to moderate liver impairment compared to those with normal liver function. It aims to help doctors understand the right dose and safety in people with liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 years or older
- Weigh at least 45 kg (females) or 50 kg (males) with a BMI between 18 and 32
- Good kidney function (creatinine clearance ≥ 60 mL/min)
- For those with liver impairment: stable chronic liver disease (Child-Pugh class A or B) and no recent major changes in health or medications
- For those with normal liver function: matched to the liver impairment group by age, weight, and gender
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a drug called HS-10365 behaves in your body if you have a stable liver condition compared to people with healthy livers. It helps doctors understand whether the dose needs to be adjusted for people with liver problems.
This trial tests an investigational drug, HS-10542, in healthy adults to see how it is processed by the body and to check for side effects. You must be willing to receive two vaccines before the study starts.
This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This Phase 1 study tests HS-20117 to see if it is safe and how well it works in people with advanced solid tumors. You may qualify if your cancer has progressed after standard treatments (or you can’t tolerate them) and you can provide new or stored tumor tissue for testing.
This trial tests a new drug called HS-20136-2 in healthy people to see how it works in the body and if it's safe. It's a Phase 1 study to gather early information before testing in patients.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation or MET-positive) and has worsened after prior treatment. It aims to see if the combination is safe and effective.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.